Array Biopharma (ARRY) Tops Q2 EPS by 10c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Array Biopharma (ARRY) Tops Q2 EPS by 10c, Revenues Beat

Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019

February 5, 2019 8:00 AM EST

BOULDER, Colo., Feb. 5, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today reported results for its second quarter of fiscal 2019 and provided an update on the progress of its key commercial products and clinical development programs.

"We continue to be pleased with demand following the U.S. launch of BRAFTOVI + MEKTOVI for patients with BRAF-mutant metastatic melanoma, which delivered $22.7 million in net product sales during the second commercial quarter," said Ron Squarer, Chief Executive Officer. "Separately, we were excited to report an unprecedented 15.3 months mature... More